Trontinemab
Medium EvidenceAn investigational, brain-penetrant anti-amyloid antibody from Roche/Genentech that uses the proprietary 'Brainshuttle' transferrin-receptor delivery system to reach the brain far more efficiently than conventional antibodies. Trontinemab (development codes RG6102 / RO7126209) is a 2+1 bispecific molecule: it fuses the amyloid-beta-clearing antibody gantenerumab to a fragment that grabs transferrin receptor 1 (TfR1) on blood-brain-barrier cells, hitching a ride into the brain via the same receptor-mediated transport that carries iron. That shuttle lets a low intravenous dose clear amyloid plaques rapidly and deeply while triggering strikingly little of the brain swelling and micro-bleeding (ARIA) that limits approved anti-amyloid drugs. In the Phase Ib/IIa Brainshuttle AD study (NCT04639050), the 3.6 mg/kg dose removed roughly 107 centiloids of amyloid after 28 weeks, driving about 91-92% of participants below the amyloid-positivity threshold (24 centiloids) - with ARIA-E seen in fewer than 5% of participants, well below the ~13% reported for lecanemab and ~24% for donanemab. On the strength of those data, Roche launched two identical pivotal Phase 3 trials - TRONTIER 1 and TRONTIER 2 - in early symptomatic Alzheimer's disease (about 1,600 patients across 18 countries, begun in 2025), and at the 2026 Alzheimer's Association International Conference (AAIC) in London it unveiled PrevenTRON, a Phase 3 prevention trial in 1,600 cognitively unimpaired people at high risk (elevated plasma p-tau217). Trontinemab is a prescription-stage investigational biologic - it is not approved anywhere and is not a supplement or research chemical.
What It Is
Trontinemab (RG6102, RO7126209) is Roche/Genentech's second-generation anti-amyloid-beta (Abeta) monoclonal antibody engineered around the company's Brainshuttle blood-brain-barrier delivery platform. Conventional therapeutic antibodies cross the blood-brain barrier very poorly - typically only about 0.1-0.3% of a systemic dose reaches the brain - which forces high, repeated infusions and is thought to contribute to amyloid-related imaging abnormalities (ARIA), the edema (ARIA-E) and microhemorrhage (ARIA-H) that constrain approved drugs like lecanemab and donanemab. Trontinemab is built as a 2+1 bispecific antibody: it binds bivalently to aggregated Abeta plaques using the gantenerumab antibody arms and monovalently to transferrin receptor 1 (TfR1) via a Fab fragment attached to the antibody's Fc domain. TfR1 is highly expressed on the endothelial cells of the blood-brain barrier and normally shuttles iron-loaded transferrin into the brain; by engaging it monovalently (which avoids receptor cross-linking and lysosomal degradation), trontinemab is actively transcytosed across the barrier and released into the brain parenchyma, achieving much greater brain exposure per dose. The molecule and its projected human dosing were first described in non-human primates (mAbs, 2023). In the open-label, dose-escalation/dose-expansion Phase Ib/IIa Brainshuttle AD study (NCT04639050), monthly intravenous trontinemab produced rapid, deep amyloid removal: at 3.6 mg/kg, mean plaque reduction was on the order of 107 centiloids at 28 weeks, with roughly 91-92% of participants falling below the 24-centiloid positivity threshold and about 72% reaching deep clearance below 11 centiloids - and these reductions were maintained through a one-year open-label extension. Critically, ARIA-E occurred in fewer than 5% of participants across the 1.8 and 3.6 mg/kg cohorts, a markedly lower rate than the ~13% (lecanemab) and ~24% (donanemab) seen with approved antibodies. On the basis of these results Roche initiated the pivotal program: TRONTIER 1 and TRONTIER 2, two identically designed Phase 3 trials enrolling about 1,600 people with early symptomatic Alzheimer's disease across 18 countries starting in 2025, with dosing informed by modeling from the Brainshuttle AD study. At AAIC 2026 in London, Roche additionally presented long-term Phase Ib/IIa extension data and the design of PrevenTRON, a Phase 3 secondary-prevention trial that will enroll 1,600 cognitively unimpaired individuals identified by elevated plasma p-tau217, using time to clinical progression as the primary endpoint. Trontinemab has no regulatory approval anywhere; it is an investigational biologic administered only within Roche's clinical trials.
Regulatory Status
Not approved by any regulator. Trontinemab is an investigational biologic being studied in Phase 3 trials (TRONTIER 1, TRONTIER 2, and the PrevenTRON prevention study); it has no FDA, EMA or other marketing authorization for any indication. It is administered by intravenous infusion only within controlled clinical trials. Any product marketed to consumers as 'trontinemab' or a 'Brainshuttle antibody' outside a regulated clinical trial is unverified and unsafe.
Why Researchers Study It
Trontinemab is the leading clinical test of active blood-brain-barrier 'shuttle' delivery for antibodies - a strategy that could reset the risk-benefit math of anti-amyloid therapy for Alzheimer's disease. Approved antibodies such as lecanemab and donanemab clear plaques and modestly slow decline, but only a tiny fraction of each dose reaches the brain, and they carry meaningful rates of ARIA (brain swelling and microbleeds) that require MRI monitoring and limit use, especially in ApoE4 carriers. By hitching gantenerumab to a transferrin-receptor shuttle, trontinemab achieves much greater brain exposure at low doses, producing some of the fastest and deepest amyloid clearance yet reported while keeping ARIA-E under ~5%. Researchers watch it as a potential proof-of-concept not just for Alzheimer's but for the whole field of brain-penetrant biologics: if the Brainshuttle platform converts dramatic amyloid removal into real cognitive benefit in TRONTIER 1/2 - and can be pushed upstream into prevention via PrevenTRON - it would validate receptor-mediated transcytosis as a general tool for delivering antibodies, enzymes and other large molecules into the central nervous system.
Proposed Mechanisms
- Brainshuttle receptor-mediated transcytosis: a Fab fragment binds transferrin receptor 1 (TfR1) on blood-brain-barrier endothelial cells and exploits the receptor's natural iron-transport cycle to actively ferry the antibody across the barrier into the brain parenchyma, achieving far greater CNS exposure than conventional antibodies (which cross only ~0.1-0.3% of dose)
- 2+1 bispecific architecture: the molecule binds bivalently to aggregated amyloid-beta (via the gantenerumab arms) and monovalently to TfR1; monovalent receptor engagement avoids cross-linking and lysosomal degradation of the receptor, preserving transferrin transport and enabling efficient shuttle delivery
- Amyloid-beta plaque clearance: once in the brain, the gantenerumab-derived arms opsonize fibrillar Abeta plaques and recruit microglia to phagocytose and remove them, driving rapid, deep reductions in amyloid burden measured by PET centiloids
- Lower-dose, lower-ARIA profile: because the shuttle concentrates antibody in the brain at low systemic doses, plaque removal is achieved with amyloid-related imaging abnormalities with edema (ARIA-E) in fewer than 5% of participants - well below the ~13% (lecanemab) and ~24% (donanemab) rates - potentially widening the treatable population and easing MRI-monitoring burden
- Upstream/preventive rationale: by clearing amyloid earlier and more completely (including in cognitively unimpaired, p-tau217-positive individuals in PrevenTRON), trontinemab tests whether deeper, earlier plaque removal can delay or prevent the clinical onset of Alzheimer's disease rather than only slow established disease
Evidence Snapshot
| Study Type | Model | Outcome | Link |
|---|---|---|---|
| Phase Ib/IIa dose-escalation and dose-expansion (Brainshuttle AD, NCT04639050) | Adults with Alzheimer's disease receiving monthly intravenous trontinemab across ascending dose cohorts (including 1.8 mg/kg and 3.6 mg/kg); amyloid burden measured by PET (centiloids), with safety MRI for ARIA | Rapid, deep amyloid clearance: mean reduction of ~107 centiloids at 3.6 mg/kg after 28 weeks; ~91-92% of participants fell below the 24-centiloid positivity threshold and ~72% reached deep clearance (<11 centiloids). ARIA-E occurred in <5% of participants across the 1.8 and 3.6 mg/kg cohorts. | Source |
| Phase Ib/IIa open-label extension (long-term data presented at AAIC 2026) | Continued monthly dosing in Brainshuttle AD participants followed through a one-year extension; long-term safety, amyloid removal and fluid/imaging biomarkers | Amyloid reductions from the core study were maintained across the one-year extension with a continued favorable ARIA profile; supportive biomarker changes reported. These data informed the dosing regimen for the pivotal Phase 3 program. | Source |
| Phase 3 pivotal trials in early symptomatic Alzheimer's (TRONTIER 1 and TRONTIER 2) | Two identically designed randomized trials enrolling ~1,600 people with early symptomatic Alzheimer's disease across 18 countries; initiated in 2025; clinical (cognition/function) primary endpoints | Ongoing - designed to test whether trontinemab's rapid, deep amyloid clearance translates into slowing of cognitive and functional decline. Efficacy results are pending (not yet reported). | Source |
| Phase 3 secondary-prevention trial (PrevenTRON; design unveiled at AAIC 2026, London) | ~1,600 cognitively unimpaired individuals at high risk of progression, identified by elevated plasma p-tau217; primary endpoint time to clinical progression | Planned/initiating - tests whether earlier, deeper amyloid removal can delay or prevent the clinical onset of Alzheimer's disease in the preclinical stage. No outcomes yet. | Source |
| Preclinical delivery study in non-human primates (mAbs, 2023) | Cynomolgus monkeys dosed with the Brainshuttle Abeta-antibody fusion; brain uptake quantified and human efficacious dose regimens projected | Demonstrated substantially enhanced brain delivery via TfR1-mediated transcytosis versus a conventional antibody, providing the translational basis for the low-dose human regimens later tested in Brainshuttle AD. | Source |
Commonly Discussed Benefits
Researching Trontinemab? Track it, set reminders, and keep notes in the free app.
Safety & Cautions
- Trontinemab is an investigational biologic with no regulatory approval anywhere; it is not a supplement or research chemical, and any product sold as 'trontinemab' or a 'Brainshuttle antibody' outside a regulated clinical trial is unverified and unsafe.
- Its clinical benefit is unproven: dramatic amyloid-plaque clearance on PET is a biomarker effect, and whether that translates into meaningful slowing of cognitive and functional decline will not be known until the Phase 3 TRONTIER 1/2 (and PrevenTRON) trials read out.
- As an anti-amyloid antibody it can still cause amyloid-related imaging abnormalities (ARIA-E edema and ARIA-H microhemorrhage); although ARIA-E was under ~5% in early studies, ARIA can be serious and requires MRI monitoring, and risk may be higher in ApoE4 carriers.
- It is delivered only by intravenous infusion within clinical trials; it is not something that can be self-administered, and dosing/eligibility are tightly controlled.
- Long-term safety, efficacy across genotypes and disease stages, and durability of benefit remain undefined; the drug is early in its pivotal program.
- Anti-amyloid therapy is not appropriate for everyone with memory complaints; diagnosis, amyloid confirmation and risk assessment must be done by qualified clinicians. This information is educational and not medical advice.
Comparisons
See how Trontinemab compares to related peptides:
Calculator Tools
Use our research tools to explore dosing and reconstitution data:
Citations
- [1] Trontinemab Phase 3 Alzheimer Trials to Launch Following Promising Amyloid Clearance Data - Patient Care Online PubMed
- [2] Roche Unveils PrevenTRON, a Phase 3 Prevention Trial of Trontinemab in Cognitively Unimpaired Individuals at High Risk of Alzheimer Decline - NeurologyLive PubMed
- [3] Roche presents new data in Alzheimer's disease from across its integrated pharmaceutical and diagnostics portfolio at AAIC (July 7, 2026) PubMed
- [4] Roche Is Back in Alzheimer's as Latest Antibody Clears Amyloid Plaques - BioSpace PubMed
- [5] TRONTIER 1 and TRONTIER 2: Pivotal trials of trontinemab in early symptomatic Alzheimer's disease - PMC PubMed
- [6] Delivery of the Brainshuttle amyloid-beta antibody fusion trontinemab to non-human primate brain and projected efficacious dose regimens in humans (mAbs, 2023) - PubMed PubMed
- [7] Trontinemab - ALZFORUM therapeutics PubMed
Keep researching in the app
- Log Trontinemab to your private tracker
- Set a dosing reminder
- Compare it side-by-side with your stack
Related Peptides
Cerebrolysin
Medium EvidenceA porcine brain-derived peptide mixture approved in some countries for stroke recovery and neurodegenerative conditions.
Davunetide
Low EvidenceAn eight-amino-acid ADNP-derived peptide studied for microtubule stabilization, tau-related neuroprotection, and rare ADNP syndrome.
Dihexa
Low EvidenceA hexapeptide analog studied for cognitive enhancement via hepatocyte growth factor pathway activation.
Humanin
Low EvidenceAn endogenous mitochondrial-derived peptide studied for neuroprotection, cellular stress resistance, and longevity, whose blood levels fall with age and are elevated in centenarians.
Klotho (Alpha-Klotho)
Low EvidenceA naturally occurring longevity hormone (secreted alpha-klotho) being studied for cognition and brain aging; a single low-dose injection improved memory in aged monkeys, and a first-in-human Phase 1 trial in older adults is underway.
P21
Medium EvidenceAn 11-amino-acid CNTF-derived peptide studied for its ability to upregulate BDNF expression and promote neurogenesis in cognitive decline models.
Selank
Medium EvidenceA synthetic peptide analog of tuftsin studied for anxiolytic and nootropic properties.
Semax
Medium EvidenceA synthetic peptide derived from ACTH, studied for cognitive enhancement and neuroprotective effects.
Trofinetide
High EvidenceA twice-daily oral peptide analog of the IGF-1 tripeptide glycine-proline-glutamate (GPE) that is the first and only medicine approved to treat Rett syndrome. Marketed by Acadia Pharmaceuticals as Daybue, trofinetide does not correct the underlying MECP2 mutation; instead it works on the downstream consequences - it is thought to restore synaptic signaling, dampen neuroinflammation, and normalize overactive microglia and astrocytes, improving neurobehavioral symptoms. It won FDA approval in March 2023 for adults and children 2 years and older. In late 2025 the FDA cleared a dye- and preservative-free powder formulation (Daybue STIX, broadly available in April 2026), and in June 2026 the EMA's CHMP adopted a positive opinion recommending European authorization.
Remternetug
Medium EvidenceRemternetug (development code LY3372993) is an investigational IgG1 monoclonal antibody from Eli Lilly that binds a pyroglutamate-modified form of amyloid-beta (N3pG-Aβ) found almost exclusively in the aggregated plaques of Alzheimer's disease. It is the follow-on to donanemab (Kisunla), Lilly's FDA-approved anti-amyloid antibody that hits the same target, and is designed to clear existing brain amyloid rapidly and, distinctively, to be delivered by a short subcutaneous injection that patients or care partners can give at home rather than only by intravenous infusion in a clinic. In an early-phase study three-quarters of treated participants reached the amyloid-clearance threshold within about six months, and remternetug is now in Phase 3 across symptomatic early Alzheimer's (TRAILRUNNER-ALZ 1), a large prevention program (TRAILRUNNER-ALZ 3), and inherited-Alzheimer prevention through the DIAN-TU network. It is not approved by the FDA or any regulator for any use.